DUBLIN--(BUSINESS WIRE)--The "Bacillary Dysentery (Shigellosis) - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.
Bacillary Dysentery (Shigellosis) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Bacillary Dysentery (Shigellosis) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Bacillary Dysentery (Shigellosis) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Bacillary Dysentery (Shigellosis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 2, 3 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 3, 2 and 1 molecules, respectively.
Key Topics Covered:
- Bacillary Dysentery (Shigellosis) - Overview
- Bacillary Dysentery (Shigellosis) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Bacillary Dysentery (Shigellosis) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Bacillary Dysentery (Shigellosis) - Companies Involved in Therapeutics Development
- Akthelia Pharmaceuticals Ltd
- GlaxoSmithKline Plc
- Immuron Ltd
- Microbiotix Inc
- Protein Potential LLC
For more information about this report visit https://www.researchandmarkets.com/research/9bb9zn/bacillary
